{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:34:55Z","timestamp":1788586495138,"version":"build-2803163510"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objectives:<\/jats:bold> Aficamten is a selective, small-molecule allosteric inhibitor of cardiac sarcomere being developed as a chronic oral treatment for patients with symptomatic obstructive hypertrophic cardiomyopathy. This was the first-in-Chinese study aiming to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of aficamten in healthy adults.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This double-blind, randomized, placebo-controlled, phase 1 study was conducted in 28 healthy male and female Chinese participants after single ascending dose (SAD) and multi-dose (MD) administrations of aficamten. In the SAD cohort, 16 participants were randomized to receive a single oral dose of aficamten: 10\u00a0mg, 20\u00a0mg, or placebo. In the MD cohort, 12 participants were randomized to receive multiple doses of aficamten: 5\u00a0mg or placebo once daily for 14\u00a0days. Safety was monitored throughout the study with electrocardiograms, echocardiograms, clinical laboratory tests, and reporting of adverse events (AEs). Pharmacokinetic profiles of aficamten and metabolites, as well as CYP2D6 genetic impact, were evaluated.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 35 treatment-emergent AEs were reported by 14 (50%) participants with mild severity. There were no serious AEs or adverse decreases in left ventricular ejection fraction below 50% during the study. Aficamten was dose-proportional over the dose range of 5\u201320\u00a0mg and accumulated in the MD cohort.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Aficamten was safe and well-tolerated in the healthy Chinese adult participants. The pharmacokinetics of aficamten in the Chinese population was comparable to those previously found in Western participants. These phase 1 data support the progression of aficamten into future clinical studies in Chinese patients.<\/jats:p><jats:p><jats:bold>Clinical Trial registration:<\/jats:bold><jats:ext-link>https:\/\/clinicaltrials.gov<\/jats:ext-link>, identifier: NCT04783766.<\/jats:p>","DOI":"10.3389\/fphar.2023.1227470","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T19:40:31Z","timestamp":1692819631000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants: a randomized, double-blind, placebo-controlled, phase 1 study"],"prefix":"10.3389","volume":"14","author":[{"given":"Xue","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijie","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s40262-013-0089-y","article-title":"Differences in cytochrome p450-mediated pharmacokinetics between Chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling","volume":"52","author":"Barter","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1016\/j.bpj.2012.04.049","article-title":"Cell-intrinsic functional effects of the \u03b1-cardiac myosin Arg-403-Gln mutation in familial hypertrophic cardiomyopathy","volume":"102","author":"Chuan","year":"2012","journal-title":"Biophys. J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","article-title":"Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy","volume":"64","author":"Chuang","year":"2021","journal-title":"J. Med. Chem."},{"key":"B4","unstructured":"REDWOOD-HCM: randomized evaluation of dosing with CK-3773274 in HCM (REDWOOD-HCM)2022"},{"key":"B5","unstructured":"CY 6031 study will evaluate the effects of treatment with aficamten (CK-3773274) over a 24-week period on cardiopulmonary exercise capacity and health status in patients with symptomatic oHCM (SEQUOIA-HCM)2022"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European society of cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur. Heart J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3760\/cma.j.issn.0253-3758.2017.12.005","article-title":"Guideline for the diagnosis and treatment of adult hypertrophic cardiomyopathy","volume":"45","year":"2017","journal-title":"Chin. J. Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3760\/cma.j.issn.2096-3076.2017.12.001","article-title":"Guidelines of hypertrophic cardiomyopathy management in China","volume":"1","year":"2017","journal-title":"Chin J Heart Fail Cardiomyopathy"},{"key":"B9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann. Intern Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jacbts.2022.04.008","article-title":"A phase 1 dose-escalation study of the cardiac myosin inhibitor aficamten in healthy participants","volume":"7","author":"Malik","year":"2022","journal-title":"JACC Basic Transl. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/01.cir.92.4.785","article-title":"Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults","volume":"92","author":"Maron","year":"1995","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e024656","DOI":"10.1161\/JAHA.121.024656","article-title":"Cardiac myosin inhibitors as a novel treatment option for obstructive hypertrophic cardiomyopathy: addressing the core of the matter","volume":"11","author":"Masri","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"B16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e533","DOI":"10.1161\/CIR.0000000000000938","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail"},{"key":"B19","volume-title":"HFSA annual scientific meeting","author":"Robertson","year":"2019"},{"key":"B20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/jvp.13103","article-title":"Pharmacokinetics of a single dose of Aficamten (CK-274) on cardiac contractility in a A31P MYBPC3 hypertrophic cardiomyopathy cat model","volume":"46","author":"Sharpe","year":"2023","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"12607","DOI":"10.1073\/pnas.1309493110","article-title":"Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human \u03b2-cardiac myosin motor function","volume":"110","author":"Sommese","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1242\/jeb.125930","article-title":"Effects of hypertrophic and dilated cardiomyopathy mutations on power output by human \u03b2-cardiac myosin","volume":"219","author":"Spudich","year":"2016","journal-title":"J. Exp. Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"eaat1199","DOI":"10.1126\/scitranslmed.aat1199","article-title":"Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin","volume":"11","author":"Toepfer","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/0002-8703(67)90303-1","article-title":"Dynamics of left ventricular emptying in hypertrophic subaortic stenosis. A cineangiographic and hemodynamic study","volume":"73","author":"Wilson","year":"1967","journal-title":"Am. Heart J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.amjmed.2003.05.009","article-title":"Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults","volume":"116","author":"Zou","year":"2004","journal-title":"Am. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1227470\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T19:40:36Z","timestamp":1692819636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1227470\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":25,"alternative-id":["10.3389\/fphar.2023.1227470"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1227470","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]},"article-number":"1227470"}}